Novartis' heart failure treatment Entresto (Sacubitril / Valsartan) is expected to be challenged by domestic companies. Interest is focused on whether domestic companies can overcome Entresto's patents, in which a total of 4 patents are registered.

According to the pharmaceutical industry on the 4th, Elyson recently filed a judgment against Novartis to confirm the scope of passive rights against Entresto's crystalline patent.

In addition to this patent, which expires on September 21, 2027, a total of four patents for Entresto are registered. Product patent expired in July 2027, and two patents for composition expired in November 2028 and January 2029. It is explained that the remaining t